These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26858375)

  • 1. No Shot: US Vaccine Prices And Shortages.
    Ridley DB; Bei X; Liebman EB
    Health Aff (Millwood); 2016 Feb; 35(2):235-41. PubMed ID: 26858375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine shortages eliminate possibility for excess capacity in stockpiles.
    Congeni BL
    Pediatr Ann; 2004 Sep; 33(9):577-83. PubMed ID: 15462572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
    Gupta R; Dhruva SS; Fox ER; Ross JS
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine shortages: history, impact, and prospects for the future.
    Hinman AR; Orenstein WA; Santoli JM; Rodewald LE; Cochi SL
    Annu Rev Public Health; 2006; 27():235-59. PubMed ID: 16533116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Shortages on Medication Prices: Implications for Shortage Prevention.
    Alevizakos M; Detsis M; Grigoras CA; Machan JT; Mylonakis E
    Drugs; 2016 Oct; 76(16):1551-1558. PubMed ID: 27770351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
    Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
    Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee.
    Santoli JM; Peter G; Arvin AM; Davis JP; Decker MD; Fast P; Guerra FA; Helms CM; Hinman AR; Katz R; Klein JO; Koslap-Petraco MB; Paradiso PR; Schaffner W; Whitley-Williams PN; Williamson DE; Gellin B;
    JAMA; 2003 Dec; 290(23):3122-8. PubMed ID: 14679275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening the supply of routinely recommended vaccines in the United States: a perspective from the American Medical Association.
    Tan L;
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S121-4. PubMed ID: 16447133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of vaccine supply.
    Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
    [No Abstract]   [Full Text] [Related]  

  • 10. U.S. vaccine and immune globulin product shortages, 2001-15.
    Ziesenitz VC; Mazer-Amirshahi M; Zocchi MS; Fox ER; May LS
    Am J Health Syst Pharm; 2017 Nov; 74(22):1879-1886. PubMed ID: 28970246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the national pediatric vaccine stockpile: supply shortages, health impacts and cost consequences.
    Shrestha SS; Wallace GS; Meltzer MI
    Vaccine; 2010 Aug; 28(38):6318-32. PubMed ID: 20638451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triage in the nation's medicine cabinet: the puzzling scarcity of vaccines and other drugs.
    Noah L
    S C Law Rev; 2002; 54(2):371-403. PubMed ID: 15156891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report predicts burgeoning vaccine markets.
    Dove A
    Nat Med; 2001 Aug; 7(8):877. PubMed ID: 11479604
    [No Abstract]   [Full Text] [Related]  

  • 15. Strengthening the supply of routinely administered vaccines in the United States: problems and proposed solutions.
    Klein JO; Myers MG
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S97-103. PubMed ID: 16447139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keys to strengthening the supply of routinely recommended vaccines: view from industry.
    Pisano W
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S111-7. PubMed ID: 16447131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with the pricing of childhood vaccines in the U.S. public sector.
    Chen W; Messonnier M; Zhou F
    Health Econ; 2018 Feb; 27(2):252-265. PubMed ID: 28660666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wyeth Pharmaceutical's perspective on vaccine production.
    Stiles GL
    Md Med; 2005; 6(1):22-3. PubMed ID: 15869103
    [No Abstract]   [Full Text] [Related]  

  • 19. Setting prices for new vaccines (in advance).
    McGuire TG
    Int J Health Care Finance Econ; 2003 Sep; 3(3):207-24. PubMed ID: 14626000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine supply: a cross-national perspective.
    Danzon PM; Pereira NS; Tejwani SS
    Health Aff (Millwood); 2005; 24(3):706-17. PubMed ID: 15886165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.